These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21782770)

  • 1. Systematic review: Patterns of proton pump inhibitor use and adherence in gastroesophageal reflux disease.
    Hungin AP; Hill C; Molloy-Bland M; Raghunath A
    Clin Gastroenterol Hepatol; 2012 Feb; 10(2):109-16. PubMed ID: 21782770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited.
    Lada MJ; Nieman DR; Han M; Timratana P; Alsalahi O; Peyre CG; Jones CE; Watson TJ; Peters JH
    Surgery; 2013 Oct; 154(4):856-64; discussion 864-6. PubMed ID: 24074425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
    Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
    Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low levels of adherence with proton pump inhibitor therapy contribute to therapeutic failure in gastroesophageal reflux disease.
    Dal-Paz K; Moraes-Filho JP; Navarro-Rodriguez T; Eisig JN; Barbuti R; Quigley EM
    Dis Esophagus; 2012 Feb; 25(2):107-13. PubMed ID: 21777341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.
    Gosselin A; Luo R; Lohoues H; Toy E; Lewis B; Crawley J; Duh MS
    Value Health; 2009; 12(1):34-9. PubMed ID: 19895371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of correlation between gastroesophageal reflux disease symptoms and esophageal lesions after sleeve gastrectomy.
    Soricelli E; Casella G; Baglio G; Maselli R; Ernesti I; Genco A
    Surg Obes Relat Dis; 2018 Jun; 14(6):751-756. PubMed ID: 29571635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
    Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
    Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
    Freedberg DE; Kim LS; Yang YX
    Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of proton pump inhibitors in infantile gastroesophageal reflux disease.
    Higginbotham TW
    Ann Pharmacother; 2010 Mar; 44(3):572-6. PubMed ID: 20124466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus.
    Baldaque-Silva F; Vieth M; Debel M; Håkanson B; Thorell A; Lunet N; Song H; Mascarenhas-Saraiva M; Pereira G; Lundell L; Marschall HU
    World J Gastroenterol; 2017 May; 23(17):3174-3183. PubMed ID: 28533674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Insufficient symptom control under long-term treatment with PPI in GERD - fact or fiction?].
    Labenz J; Labenz G; Stephan D; Willeke F;
    MMW Fortschr Med; 2016 May; 158 Suppl 4():7-11. PubMed ID: 27221555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease.
    Hillman L; Yadlapati R; Thuluvath AJ; Berendsen MA; Pandolfino JE
    Dis Esophagus; 2017 Sep; 30(9):1-15. PubMed ID: 28859358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mealtime-related dosing directions for proton-pump inhibitors in gastroesophageal reflux disease: physician knowledge, patient adherence.
    Solem C; Mody R; Stephens J; Macahilig C; Gao X
    J Am Pharm Assoc (2003); 2014; 54(2):144-53. PubMed ID: 24632930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastroesophageal reflux disease-related symptom recurrence in patients discontinuing proton pump inhibitors for Bravo
    Schey R; Alla SP; Midani D; Parkman HP
    Rev Gastroenterol Mex; 2017; 82(4):277-286. PubMed ID: 28385467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proton pump inhibitor prescriptions and subsequent use in US veterans diagnosed with gastroesophageal reflux disease.
    Gawron AJ; Pandolfino JE; Miskevics S; Lavela SL
    J Gen Intern Med; 2013 Jul; 28(7):930-7. PubMed ID: 23400526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015.
    Iwakiri K; Kinoshita Y; Habu Y; Oshima T; Manabe N; Fujiwara Y; Nagahara A; Kawamura O; Iwakiri R; Ozawa S; Ashida K; Ohara S; Kashiwagi H; Adachi K; Higuchi K; Miwa H; Fujimoto K; Kusano M; Hoshihara Y; Kawano T; Haruma K; Hongo M; Sugano K; Watanabe M; Shimosegawa T
    J Gastroenterol; 2016 Aug; 51(8):751-67. PubMed ID: 27325300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns and symptom control in patients with GERD: US community-based survey.
    Chey WD; Mody RR; Wu EQ; Chen L; Kothari S; Persson B; Beaulieu N; Lu M
    Curr Med Res Opin; 2009 Aug; 25(8):1869-78. PubMed ID: 19530980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
    Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
    Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis.
    Chen CH; Lin CL; Kao CH
    Osteoporos Int; 2016 Jun; 27(6):2117-26. PubMed ID: 26860609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.